369 related articles for article (PubMed ID: 30169827)
1. Targeting kidney inflammation as a new therapy for primary hyperoxaluria?
Martin-Higueras C; Ludwig-Portugall I; Hoppe B; Kurts C
Nephrol Dial Transplant; 2019 Jun; 34(6):908-914. PubMed ID: 30169827
[TBL] [Abstract][Full Text] [Related]
2. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure.
Hoppe B; Kemper MJ; Bökenkamp A; Portale AA; Cohn RA; Langman CB
Kidney Int; 1999 Jul; 56(1):268-74. PubMed ID: 10411702
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of a novel rat model of primary hyperoxaluria type 1 with a nonsense mutation in alanine-glyoxylate aminotransferase gene.
Li Y; Zheng R; Xu G; Huang Y; Li Y; Li D; Geng H
Am J Physiol Renal Physiol; 2021 Mar; 320(3):F475-F484. PubMed ID: 33491567
[TBL] [Abstract][Full Text] [Related]
4. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I.
Worcester EM; Evan AP; Coe FL; Lingeman JE; Krambeck A; Sommers A; Phillips CL; Milliner D
Am J Physiol Renal Physiol; 2013 Dec; 305(11):F1574-84. PubMed ID: 24089413
[TBL] [Abstract][Full Text] [Related]
5. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy.
Knauf F; Asplin JR; Granja I; Schmidt IM; Moeckel GW; David RJ; Flavell RA; Aronson PS
Kidney Int; 2013 Nov; 84(5):895-901. PubMed ID: 23739234
[TBL] [Abstract][Full Text] [Related]
6. The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury.
Anders HJ; Suarez-Alvarez B; Grigorescu M; Foresto-Neto O; Steiger S; Desai J; Marschner JA; Honarpisheh M; Shi C; Jordan J; Müller L; Burzlaff N; Bäuerle T; Mulay SR
Kidney Int; 2018 Mar; 93(3):656-669. PubMed ID: 29241624
[TBL] [Abstract][Full Text] [Related]
7. Oxalate, inflammasome, and progression of kidney disease.
Ermer T; Eckardt KU; Aronson PS; Knauf F
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):363-71. PubMed ID: 27191349
[TBL] [Abstract][Full Text] [Related]
8. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
Chetyrkin SV; Kim D; Belmont JM; Scheinman JI; Hudson BG; Voziyan PA
Kidney Int; 2005 Jan; 67(1):53-60. PubMed ID: 15610227
[TBL] [Abstract][Full Text] [Related]
9. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
Lai C; Pursell N; Gierut J; Saxena U; Zhou W; Dills M; Diwanji R; Dutta C; Koser M; Nazef N; Storr R; Kim B; Martin-Higueras C; Salido E; Wang W; Abrams M; Dudek H; Brown BD
Mol Ther; 2018 Aug; 26(8):1983-1995. PubMed ID: 29914758
[TBL] [Abstract][Full Text] [Related]
10. Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria.
Bollée G; Cochat P; Daudon M
Can J Kidney Health Dis; 2015; 2():31. PubMed ID: 26380104
[TBL] [Abstract][Full Text] [Related]
11. Potential for bilateral nephrectomy to reduce oxalate release after combined liver and kidney transplantation for primary hyperoxaluria type 1.
Mizusawa Y; Parnham AP; Falk MC; Burke JR; Nicol D; Yamanaka J; Lynch SV; Strong RW
Clin Transplant; 1997 Oct; 11(5 Pt 1):361-5. PubMed ID: 9361924
[TBL] [Abstract][Full Text] [Related]
12. Bilateral native nephrectomy reduces systemic oxalate level after combined liver-kidney transplant: A case report.
Villani V; Gupta N; Elias N; Vagefi PA; Markmann JF; Paul E; Traum AZ; Yeh H
Pediatr Transplant; 2017 May; 21(3):. PubMed ID: 28261895
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure.
Zhao F; Bergstralh EJ; Mehta RA; Vaughan LE; Olson JB; Seide BM; Meek AM; Cogal AG; Lieske JC; Milliner DS;
Clin J Am Soc Nephrol; 2016 Jan; 11(1):119-26. PubMed ID: 26656319
[TBL] [Abstract][Full Text] [Related]
14. [Primary hyperoxaluria: A review].
Bouzidi H; Majdoub A; Daudon M; Najjar MF
Nephrol Ther; 2016 Nov; 12(6):431-436. PubMed ID: 27372182
[TBL] [Abstract][Full Text] [Related]
15. An update on primary hyperoxaluria.
Hoppe B
Nat Rev Nephrol; 2012 Jun; 8(8):467-75. PubMed ID: 22688746
[TBL] [Abstract][Full Text] [Related]
16. Navigating the Evolving Landscape of Primary Hyperoxaluria: Traditional Management Defied by the Rise of Novel Molecular Drugs.
Huang Y; Zhu W; Zhou J; Huang Q; Zeng G
Biomolecules; 2024 Apr; 14(5):. PubMed ID: 38785918
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.
Dutta C; Avitahl-Curtis N; Pursell N; Larsson Cohen M; Holmes B; Diwanji R; Zhou W; Apponi L; Koser M; Ying B; Chen D; Shui X; Saxena U; Cyr WA; Shah A; Nazef N; Wang W; Abrams M; Dudek H; Salido E; Brown BD; Lai C
Mol Ther; 2016 Apr; 24(4):770-8. PubMed ID: 26758691
[TBL] [Abstract][Full Text] [Related]
18. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1.
Hoppe B; Beck B; Gatter N; von Unruh G; Tischer A; Hesse A; Laube N; Kaul P; Sidhu H
Kidney Int; 2006 Oct; 70(7):1305-11. PubMed ID: 16850020
[TBL] [Abstract][Full Text] [Related]
19. Primary hyperoxaluria: clinical course, diagnosis, and treatment after kidney failure.
Raju DL; Cantarovich M; Brisson ML; Tchervenkov J; Lipman ML
Am J Kidney Dis; 2008 Jan; 51(1):e1-5. PubMed ID: 18155525
[TBL] [Abstract][Full Text] [Related]
20. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1.
Kukreja A; Lasaro M; Cobaugh C; Forbes C; Tang JP; Gao X; Martin-Higueras C; Pey AL; Salido E; Sobolov S; Subramanian RR
Nucleic Acid Ther; 2019 Apr; 29(2):104-113. PubMed ID: 30676254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
